Nephrology
News
SGLT2 inhibitor use rising in patients with DKD
News
PCPs lag on albuminuria tests in patients with type 2 diabetes
News
New drug, finerenone, approved for slowing kidney disease in diabetes
Finerenone (Kerendia) is the first agent approved from a novel class, the nonsteroidal mineralocorticoid receptor antagonists. But its role in...
Conference Coverage
‘Stunning’ twincretin beats semaglutide for A1c, weight reduction in T2D
Head-to-head pivotal trial results show weekly tirzepatide injections surpassed 1 mg semaglutide weekly for A1c reduction and weight loss.
Conference Coverage
Half of patients in hospital for COVID-19 get acute kidney injury
It’s bad news when hospitalized COVID-19 patients develop acute kidney injury, which can prove fatal or can lead to the development or worsening...
News
Bone loss common in kidney stone patients, yet rarely detected
Almost one-quarter of patients diagnosed with kidney stones have osteoporosis or a fracture history on diagnosis, yet few undergo bone mineral...
Article
New skin papules
The location of the patient’s lesions, as well as her underlying conditions, pointed to the diagnosis.
News
Further warning on SGLT2 inhibitor use and DKA risk in COVID-19
Five new cases of euglycemic diabetic ketoacidosis seen in T2D patients with acute COVID-19 illness.
News
ADA 2021 standards address financial hardship in diabetes
In the year of COVID-19, new ADA standards include assessment of socioeconomic challenges, individualization of type 2 diabetes treatment, and...
Conference Coverage
Finerenone’s heart benefits hold up in T2D patients without CVD
In the FIDELIO-DKD trial, cardiovascular benefits from a nonsteroidal mineralocorticoid antagonist held, regardless of CVD history, in T2D...